Brain insulin resistance: role in neurodegenerative disease and potential for targeting
Christian Hölscher
Abstract
: Insulin, GLP-1 and GIP receptor agonists have shown good effects in preclinical studies. First clinical trials in MCI/AD patients have shown that insulin can improve on key pathological symptoms of AD such as memory impairment, brain activity, neuronal energy utilization, and inflammation markers. A GLP-1 receptor agonist has shown disease-modifying effects in PD patients, and first pilot studies have shown encouraging effects of a GLP-1 receptor agonist in AD patients. Novel dual GLP-1/GIP receptor agonists that cross the blood brain barrier show superior neuroprotective effects compared to single GLP-1 or GIP receptor agonists, and show great promise as novel treatments of AD and PD.
Topics & Concepts
NeuroprotectionMedicineAgonistReceptorInsulin resistanceGlucagon-like peptide 1 receptorInsulin receptorInsulinDiseaseInternal medicineEndocrinologyPharmacologyNeuroscienceBiologyDiabetes Treatment and ManagementPancreatic function and diabetesMetabolism, Diabetes, and Cancer